KRYS Q3'26 Earnings: revenue estimate is 126.22M USD

What happened

Krystal Biotech will report Q3'26 results on November 02 before the market opens at 7:00 AM ET. Analysts estimate revenue of 126.22 million USD and earnings per share of 1.82 USD, according to FactSet data.

Confirmed

Global impact / market context

Hitting the revenue and profit targets would signal steady demand, while a miss could pressure the stock because investors pay for expected future growth. Earnings per share is profit divided by shares, which means profit per ownership unit.

Analyst inference

Previous quarters show revenue mostly beat estimates, though the latest reported quarter missed. Earnings per share beat estimates in every listed quarter, which means actual profit per share topped forecasts. That record raises expectations for another beat.

Analyst inference

What to watch

1. Watch whether reported Q3'26 revenue reaches the 126.22 million USD estimate, which would show whether sales growth is continuing at the pace analysts expect. Confirmed
2. Watch whether earnings per share meet the 1.82 USD estimate, since past quarters show profit per share beating forecasts, which means actual results topped analyst expectations each time. Proposed
3. Watch any change in company spending plans or costs, because higher costs would reduce profit per sale and could lower future earnings even if revenue meets estimates. Analyst inference

Evidence

• Original source link unavailable